Weekly Sugar Wrap
Written by Howard Jenkins, Head of Global Commodities
The main event of the week was the exciting news that a vaccine for Covid has been developed with impressive 90% ability in preventing the virus. This news sent the equity and crude markets soaring overshadowing the US election shenanigans. While there is still much work to be done before available for mass-vaccination it has brightened things considerable. Several other vaccines are also looking promising. Oddly, sugar seemed unmoved by the news as the recent volatility subsided and the market has became range-bound as all await any proclamation from the Indian government’s on their export policy.
As ever, conflicting reports continue to emerge from ‘Government sources’ regarding the export policy to be adopted. It now would seem 6 million tonnes of exports will be the aim but the all-important subsidy is, as yet, not forthcoming. Perhaps next week? Undoubtable, India will need to export otherwise the all-important domestic price will collapse adding to Mills financial woes. The government will be mindful that production should be robust in 2021/22 after another wet monsoon. If the subsidy is pitched too low then exports could be limited. One way or the other it is likely to immediately put a ceiling on prices which may trigger the funds to take their profits.
Unica released their harvest data for second half of October. While the figures were broadly in line with expectations it is interesting to note that total sugar production for the CS has already reached a new record of 36.41 million tonnes. There were over 200 mills still crushing at the end of October suggesting the final total could be around 38 million tonnes a record which is likely to stand for some time.
Today sees the December contract expiry in London. Currently, it looks likely the delivery will be a very large +600ktonnes. The usual debate will the ensue as to whether it is bullish or bearish. However, remember that the record delivery in October raws had the same debate. In hindsight many would now conclude it was bullish.
Uncertainty will continue to haunt the markets despite talk of vaccines. The sugar world awaits the Indian government – however, any announcement may well throw up more questions than answers.
Contact the ADMISI Sugar Desk team:
Howard Jenkins, Charles Branch, Kevin Watkins, Steven Trigg
Phone: +44(0) 207 716 8598
Registered in England No. 2547805 a subsidiary of Archer Daniels Midland Company. Risk Warning: Investments in Equities, CFDs, Futures, Options, Derivatives and Foreign Exchange can fluctuate in value, investors should therefore be aware that they may not realise the initial amount invested, and indeed may incur additional liabilities. These Investments may entail above average financial risk of loss, and investors should therefore carefully consider whether their financial circumstances and investment experience permit them to invest and, if necessary, seek the advice of an independent Financial Advisor. Some services described are not available to certain customers due to regulatory constraints either in the United Kingdom or elsewhere.
Risk Warning: Investments in Equities, Contracts for Difference (CFDs) in any instrument, Futures, Options, Derivatives and Foreign Exchange can fluctuate in value. Investors should therefore be aware that they may not realise the initial amount invested and may incur additional liabilities. These investments may be subject to above average financial risk of loss. Investors should consider their financial circumstances, investment experience and if it is appropriate to invest. If necessary, seek independent financial advice.
ADM Investor Services International Limited, registered in England No. 2547805, is authorised and regulated by the Financial Conduct Authority [FRN 148474] and is a member of the London Stock Exchange. Registered office: 3rd Floor, The Minster Building, 21 Mincing Lane, London EC3R 7AG.
A subsidiary of Archer Daniels Midland Company.
© 2021 ADM Investor Services International Limited.
Futures and options trading involve significant risk of loss and may not be suitable for everyone. Therefore, carefully consider whether such trading is suitable for you in light of your financial condition. The information and comments contained herein is provided by ADMIS and in no way should be construed to be information provided by ADM. The author of this report did not have a financial interest in any of the contracts discussed in this report at the time the report was prepared. The information provided is designed to assist in your analysis and evaluation of the futures and options markets. However, any decisions you may make to buy, sell or hold a futures or options position on such research are entirely your own and not in any way deemed to be endorsed by or attributed to ADMIS. Copyright ADM Investor Services, Inc.